Position in LKFT
as of Jun 30, 2026
· filed Jul 21, 2026
Position Value
$7,465
+$7,119 QoQ
Shares Held
249
+2390.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#59
of 78 holders
Holding Since
Sep 2022
12 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in LKFT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Blue Trust, Inc. holds $5,572,579 across 69 Biotechnology names. LKFT ranks #39 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
17,105 | $930,682 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,677 | $833,015 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
2,961 | $713,511 | |
| 4 | ACHV |
Achieve Life Sciences, Inc.
|
85,888 | $560,848 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
859 | $535,620 | |
| 6 | DMAC |
DiaMedica Therapeutics Inc.
|
69,122 | $486,618 | |
| 7 | GMAB |
Genmab A/S
|
11,676 | $320,739 | |
| 8 | ONC |
BeOne Medicines Ltd.
|
805 | $229,400 |
All Filings in LKFT
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,465 | 249 | Shares | Sole | 2026-07-21 | |
| 2025-09-30 | $346 | 10 | Shares | Sole | 2025-10-16 | |
| 2025-06-30 | $279 | 10 | Shares | Sole | 2025-07-24 | |
| 2025-03-31 | $251 | 10 | Shares | Sole | 2025-04-21 | |
| 2024-12-31 | $275 | 10 | Shares | Sole | 2025-01-30 | |
| 2024-09-30 | $14,913 | 518 | Shares | Defined | 2024-10-17 | |
| 2024-06-30 | $6,715 | 271 | Shares | Defined | 2024-07-18 | |
| 2023-12-31 | $4,308 | 106 | Shares | Defined | 2024-01-18 | |
| 2023-06-30 | $162 | 4 | Shares | Sole | 2023-07-14 | |
| 2023-03-31 | $425 | 11 | Shares | Sole | 2023-04-17 | |
| 2022-12-31 | $2,174 | 49 | Shares | Sole | 2023-01-17 | |
| 2022-09-30 | $980 | 23 | Shares | Sole | 2022-10-21 | |
| No filing history on record for this holder in this stock. | ||||||